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Abstract
Background: Gene modified dendritic cells (DC) are able to modulate DC functions and induce
therapeutic immunity or tolerance in an antigen-specific manner. Among the different DC subsets,
plasmacytoid DC (pDC) are well known for their ability to recognize and respond to a variety of
viruses by secreting high levels of type I interferon.
Methods: We analyzed here, the transduction efficiency of a pDC cell line, GEN2.2, and of pDC
derived from CD34+ progenitors, using lentiviral vectors (LV) pseudotyped with different envelope
glycoproteins such as the vesicular stomatitis virus envelope (VSVG), the gibbon ape leukaemia
virus envelope (GaLV) or the feline endogenous virus envelope (RD114). At the same time, we
evaluated transgene expression (E-GFP reporter gene) under the control of different promoters.
Results: We found that efficient gene transfer into pDC can be achieved with VSVG-pseudotyped
lentiviral vectors (LV) under the control of phoshoglycerate kinase (PGK) and elongation factor-1
(EF1α) promoters (28% to 90% of E-GFP+ cells, respectively) in the absence of phenotypic and
functional maturation. Surprisingly, promoters (desmin or synthetic C5–12) described as muscle-
specific and which drive gene expression in single strand AAV vectors in gene therapy protocols
were very highly active in pDC using VSVG-LV.
Conclusion: Taken together, our results indicate that LV vectors can serve to design pDC-based
vaccines in humans, and they are also useful in vitro to evaluate the immunogenicity of the vector
preparations, and the specificity and safety of given promoters used in gene therapy protocols.
Background
Dendritic cells (DC) are antigen-presenting cells (APC)
with a role in controlling the balance between immunity
and immunological tolerance [1,2]. In humans, at least
two subsets of DC are known in the blood, myeloid DC
(also known as interstitial or dermal DC), and plasmacy-
toid DC (pDC) and Langerhans cells (LC) in the tissues
[3]. Plasmacytoid DC also called "natural interferon pro-
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ducing cells" (NIPC), represent 0.2–0.8% of peripheral
blood cells and have also been found in the spleen, bone
marrow, tonsils, lymph nodes, foetal liver and thymus
[2,4-6]. Plasmacytoid DC are well known for their ability
to recognize and respond to a variety of viruses [6]. They
recognize viral genomic nucleic acids of dsDNA viruses [7-
10] and ssRNA viruses [11-13] via Toll-like receptor 9
(TLR9) and TLR7, respectively in the acidified endosomes
without becoming infected themselves. Plasmacytoid DC
are characterized by their high secretion levels of type I
interferon in response to viruses [14,15], which not only
have direct inhibitory effects on viral replication, but also
can promote the function of natural killer cells, B cells, T
cells and myeloid DC [16]. Human pDC do not express
lineage specific markers, but are characterized by the
expression of HLA-DR, CD4, CD123, BDCA2 and BDCA4
[3]. These scarce cells can be generated from CD34+ pro-
genitor cells [17]. Recently, a pDC cell line called GEN2.2
established from leukemic pDC was described as sharing
most of the phenotypic and functional features of normal
pDC [18] and so represents a good model for study of the
physiology of their normal counterpart [19].
Over the classical antigen loading methods usually con-
sidered, such as peptide or protein loading, gene modified
DC offer potential advantages: 1) they ensure long-lasting
expression of the antigen and production of an entire
array of epitopes presented by the autologous HLA mole-
cules, 2) antigens are delivered to both endogenous MHC
class I and class II antigen presentation pathways [2,20].
Lentiviral vectors (LV) pseudotyped with the vesicular sto-
matitis virus envelope glycoprotein (VSVG) are efficient
gene delivery vectors for dividing and non-dividing cells
and were shown to be applicable to many cell types
including human conventional DC and LC [21-26].
Transduced DC and LC retained their immature pheno-
type, were able to respond to maturation signals, and
maintain immunostimulatory potential in both autolo-
gous and allogeneic settings [22,26,27]. To our knowl-
edge, the transduction capacity of LV into pDC has not yet
been evaluated. LV can be pseudotyped with a variety of
envelope glycoproteins [28,29] such as the gibbon ape
leukaemia virus envelope (GaLV) or the feline endog-
enous virus envelope (RD114) which have been reported
to be efficient in the transduction of hematopoietic cells
[30-32]. The elongation factor-1α (EF1α) and
phoshoglycerate kinase (PGK) promoters were shown to
have an activity in a human CD34+ cell and in cultured
cord blood cells and transgene-expressing myeloid DC
were obtained from them [23,26,33,34].
One of the alternate vectors used to transduce monocytes
or DC was the recombinant adeno-associated virus
(rAAV) with a genome conventionally packaged as single-
stranded molecules (ss) [35-37], characterized by its abil-
ity to transduce both dividing and non-dividing cells.
Recombinant AAV is unique among viral vectors that are
being developed for gene therapy applications in that the
wild-type virus counterpart has never been shown to cause
human disease. So far, transduction efficiencies of DC
subsets have been shown to be low and variable [36,38].
In this study, we compared the transduction efficiency
into a human pDC cell line and in CD34-pDC, with i) LV
pseudotyped with different envelopes encoding E-GFP. In
this context, we also tested different promoters: two pro-
moters with high activity in hematopoietic cells (PGK and
EF1a) and two promoters described as muscle-specific
[39-41] (C5–12 and desmin) in order to evaluate the pro-
moter leak in pDC, ii) rAAV of different serotypes. We
found that efficient gene transfer into pDC can be
achieved mainly with VSVG-pseudotyped LV under the
control of PGK and EF1 promoters. Surprisingly, promot-
ers described as muscle-specific were also highly active in
pDC. Gene transfer into pDC could be of high importance
for the design of new DC-based vaccines, or for induction
of peripheral tolerance for dedicated therapeutic applica-
tions.
Methods
Culture of pDC line
Gen2.2 is a pDC cell line derived from a leukaemia
patient. Tumor cells were characterized as pDC like [18].
Briefly, they grow on a murine fibroblast feeder cell line
MS5 in RPMI, 10% FCS complemented with 1% L-
glutamine, non essential amino acids, gentamycin and
0.2% sodium pyruvate.
Lentiviral vector constructions and production
The VSV-G pseudotyped LV vectors were produced in 293
T cells by transient transfection of three plasmids, the
transfer vector (pRRL-SIN-PPT-hPGK-GFP-WPRE, pRRL-
SIN-PPT-hEF1-GFP-WPRE, pRRL-SIN-PPT-C512-GFP-
WPRE, or pRRL-SIN-PPT-desmin-GFP-WPRE or pRRL-
SIN-PPT-C512-MART1-WPRE the packaging construct
pCMVΔR8.74 and the vesicular stomatitis virus envelope-
expressing construct pMD.G. High-titer stocks were pre-
pared by ultracentrifugation as described [42]. Also,
GALV-pseudotyped LV vectors or RD114-pseudotyped LV
vectors were produced in 293 T cells by transient transfec-
tion of the transfer vector pRRL-SIN-PPT-hPGK-GFP-
WPRE, the packaging construct pCMVΔR8.74 and either
the gibbon ape leukaemia virus chimeric envelope plas-
mid (pBA-GaLV-ampho) or feline leukaemia virus type C
chimeric envelope plasmid (pBA-RD114-ampho). Vector
supernatants were also concentrated by ultracentrifuga-
tion. Expression titers were determined by flow cytometry
(FACSCalibur, Becton Dickinson, Mountain View, CA),
on C2C12 cells for LV constructs with desmin and C5–12
promotors, and on HCT116 cells for the other constructs.
Titers were 7.7 × 107 to 7.9 × 109 transducing units/ml.Journal of Translational Medicine 2009, 7:10 http://www.translational-medicine.com/content/7/1/10
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AAV vector construction and production
Pseudotyped AAV vectors were generated by packaging
AAV2-based recombinant genomes in AAV1, AAV2 or
AAV5 capsids. All the vectors used in the study were pro-
duced using the three-plasmid transfection protocol as
described elsewhere [43]. Briefly, HEK293 cells were tri-
transfected with the adenovirus helper plasmid pXX6
[44], a pAAV packaging plasmid expressing the rep and cap
genes (pACG2.1 for AAV2, pLT-RC02 for AAV1 and pLT-
RC03 for AAV5) and the relevant pAAV2 vector plasmid.
ssAAV vectors were produced with conventional pGG2
AAV2 vector plasmid expressing E-GFP under the tran-
scriptional control of the cytomegalovirus immediate
early (CMV IE) promoter associated with a SV40 polyA
signal. Recombinant vectors were purified by double-
CsCl2 ultracentrifugation followed by dialysis against ster-
ile phosphate-buffered saline (PBS). Physical particles
were quantified by real time PCR and vector titers are
expressed as viral genomes per ml (vg/ml).
Cell line
The OP9 stroma cell line coding for human delta 1 (OP9-
Del1) was kindly provided by A. Galy (Genethon, Evry,
France) and maintained as previously described [17].
Culture of peripheral blood monocytes and CD34+ 
progenitors
Monocytes were generated from normal volonteers'
monocytes after elutriation of peripheral blood according
to the french EFS procedures (Pr Jacky Bernard, Reims,
France). This method yielded purified (92.2% +/- 5.1)
CD14+CD45+ cells as assessed by flow cytometry. Briefly,
cryopreserved monocytes were cultured in 6-well plates, at
a density of 1 × 106 cells/ml in RPMI 1640 (Invitrogen Life
technology, Auckland, USA) supplemented with 10% of
FCS (Hyclone, Logan, Utah, USA) and 1% L-glutamin
(Invitrogen). Monocytes were differentiated in cDC (Mo-
DC) in presence of 50 ng/ml of recombinant human (rh)
GM-CSF (Novartis, Bâle, Switzerland), and 15 ng/ml of
rhIL-4 (Tebu-bio, le Perray, France). Maturation was
induced in some experiments by addition of LPS (7 μg/ml
Sigma-aldrich, St.Louis, MO, USA) at day 8, for 24 hours.
pDC were generated from cord blood CD34+ cells (CD34-
pDC) following protocols previously described by Olivier
et al [17]. 2 × 104 CD34+ progenitors were added onto
OP9-Del1 cells seeded one day before, in 24-well plates at
3 × 104 cells/well. Cells were cultured in RPMI 1640 (Inv-
itrogen) supplemented with 10% FCS (Hyclone), 1% L-
glutamine and 1% Penicillin/Streptomycin (Gibco) in the
presence of recombinant human Fms-like tyrosine kinase-
3-Ligand (FLT3-L; 5 ng/ml) and rIL-7 (5 ng/ml; R&D Sys-
tems, Minneapolis, MN). Maturation of CD34-pDC was
induced in some experiments by addition of CpG oligode-
oxynucleotide type A (ODN 2216 at 2 μM) at day 10, for
24 hours. All cells were cultured in a humidified incubator
at 37°C and 5% CO2.
Transduction of GEN2.2
GEN2.2 were transduced by lentiviral vectors at multiplic-
ity of infection (MOI) of 18 TU/ml or adeno-associated
vector at 9 × 103 to 25 × 103 viral genome (Vg)/cell. Trans-
ductions were carried out just after thawing at a fixed con-
centration of 2–5 × 106  of cells per 200–500 μl of
medium. After 3 hours at 37°C, cells were placed in com-
plete medium and analysed by flow cytometry between
day 5 and day 60.
Transduction of CD34-pDC
Semi-adherent and non-adherent cells in culture were har-
vested at day 6 and transduced by LV-VSVG-PGK at an
MOI of 18 TU/ml and at a fixed concentration of 1 × 106
cells/ml, in RPMI 1640. After 3 hours at 37°C, cells were
replaced in the same complete medium then cultured for
5–6 additional days.
Transduction of monocytes
After thawing, monocytes were transduced by LV-VSVG-
PGK at an MOI of 18 TU/ml and at a fixed concentration
of 1 × 106 cells/ml respectively, in RPMI 1640. After 3
hours at 37°C, cells were cultured in complete medium as
described above to generate Mo-DC.
ELISA
Human interferon-α levels were determined using specific
ELISA kit (R&D Systems, Minneapolis, MN). Lower limit
of detection was 10 pg/ml.
Mixed leukocyte reaction (MLR)
Enriched naïve CD45RA+ T-cells were recovered after elu-
triation of monocytes. This method yielded purified
(83.6% +/- 7.3) CD45RA+cells as assessed by flow cytom-
etry. CD45RA+T cells were labelled with carboxyfluores-
cein diacetate succinimidyl ester (CFSE) at a final
concentration of 0.5 μM, for 20 min at 37°C before being
extensively washed. E-GFP negative and positive GEN2.2
were sorted on a MoFlow cytometer (Dako, Glostrup,
Denmark). For the mixed leukocyte reaction, CpG
matured allogeneic pDC were extensively washed and cul-
tured in 96-well U-bottom plates at different cell numbers
with 1 × 105 CFSE labelled CD45RA++ T-cells. On day 4,
cells were harvested, washed, labelled for T specificity
with anti-CD3 antibody and analysed by flow cytometry.
The percentage of dividing T-cells was linearly correlated
with the decrease in CFSE fluorescence.
Activation of a MART-1 CD8+ T cell clone by transduced 
DC subpopulations
Matured HLA-A2+ DC subpopulations were obtained after
transduction of cells by LV coding for a MART-1 peptideJournal of Translational Medicine 2009, 7:10 http://www.translational-medicine.com/content/7/1/10
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using a PGK promoter. Non-transduced matured HLA-
A2+  GEN2.2, CD34-pDC and Mo-DC and transduced
GEN2.2 cells, CD34-pDC and Mo-DC were co-cultured in
96-well U-bottom plates at different ratios with 1 × 105
cells/well of a specific MART-1 CD8+ T-cell clone HLA-A2
restricted (LT12) and labelled with CFSE as described ear-
lier for the MLR. On day 5, cells were harvested, washed,
labelled with an anti-CD8 antibody and analysed by flow
cytometry. The percentage of dividing T-cells was linearly
correlated with the loss in CFSE fluorescence.
Flow cytometric analysis
The pDC phenotype was assessed using three color immu-
nostaining with biotinylated, phycoerythrin (PE)-, Cy-
Chrome (CyC)-and allophycocyanin (APC) -conjugated
monoclonal anti-CD40 (5C3), anti-CD80 (L307.4),
CD83 (HB15e), anti-CD86 (FUN-1), anti-HLA-DR
(G46.6) antibodies (purchased from Becton Dickinson,
Mountain View, CA, Pharmingen product, San Diego, CA)
and anti-BDCA2 (AC-144), anti-BDCA4 (AD5-17F6) and
anti-CD123 (AC145) (from Miltenyi Biotech). Data were
Transduction efficiencies of GEN2.2 Figure 1
Transduction efficiencies of GEN2.2. The pDC cell line, GEN2.2, was non-transduced (NT) or transduced with E-GFP 
encoding vectors then analysed 5 days posttransduction. GEN2.2 were gated in forward/side scatter, then analyzed for the 
expression E-GFP by flow cytometry. (A) GEN2.2 were transduced by LV with a PGK promoter pseudotyped with either 
VSVG and RD114 envelopes at a MOI of 18 or with the GaLV envelope at a MOI of 9. (B) GEN2.2 were transduced with 
VSVG pseudotyped-LV with a PGK, EF1, desmin or C5–12 promoter, at a MOI of 18. (C) GEN2.2 were transduced by rAAV 
of serotype 1, 2 or 5 with a CMV promoter, with the number of viral genomes/cell indicated. Results are expressed as mean 
percentage of cell +/- SD over the number of independent experiments indicated.Journal of Translational Medicine 2009, 7:10 http://www.translational-medicine.com/content/7/1/10
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acquired using a FACSCalibur flow cytometer (Becton
Dickinson) and data analysis was performed using the
CellQuest program (Becton Dickinson).
Statistical analyses
Results were presented as the mean +/- standard devia-
tion. Student's t-test for paired data was use to determine
significant differences between the two groups. A p-
value<0.05 was considered statistically significant.
Results
Transduction of pDC by LV and AAV vectors
We first compared the gene transfer efficiency into the
human pDC cell line, GEN2.2, and in day 6 CD34-pDC,
using LV pseudotyped with different envelopes from
VSVG, GaLV or RD114 viruses. E-GFP expression can be
easily and accurately monitored by FACS analysis. Prelim-
inary experiments performed with LV encoding E-GFP
under the control of the ubiquitous PGK promoter with
different MOI (5–50), at a fixed cell density, showed that
maximum transduction levels were reached at a MOI of
18 for VSVG-LV and RD114-LV and at a MOI of 9 for
GaLV-LV (data not shown), without cellular toxicity. pDC
were monitored for CD123, HLA-DR and E-GFP expres-
sion at day 5 to 6 posttransduction. A single exposure of
GEN2.2 to VSVG-LV or RD114-LV led to 30% +/- 11.6%
and 18.6% +/- 8% of cells which were E-GFP positive,
respectively (figure 1A). When GaLV-LV was used, how-
Transduction efficiencies of CD34-pDC Figure 2
Transduction efficiencies of CD34-pDC. CD34-pDC were non-transduced (NT) or transduced with E-GFP encoding vec-
tors at day 6 after the induction of differentiation, then cultured for 6 additional days. pDC were gated in forward/side scatter, 
then analyzed for the expression of E-GFP by flow cytometry. (A) CD34+ progenitors were transduced by LV with a PGK pro-
moter pseudotyped with either VSVG and RD114 envelopes at a MOI of 18 or with the GaLV envelope at a MOI of 9. (B) 
CD34+ progenitors were transduced with VSVG pseudotyped-LV with a PGK, EF1, desmin or C5–12 promoter, at a MOI of 
18. (C) CD34+ progenitors were transduced by rAAV of serotype 1, 2 or 5 with a CMV promoter, with the number of viral 
genomes/cell indicated. Results are expressed as mean percentage of cell +/- SD over the number of independent experiments 
indicated.Journal of Translational Medicine 2009, 7:10 http://www.translational-medicine.com/content/7/1/10
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ever, it was difficult in our hands to obtain high enough
titers to reach a MOI of 18 using similar transduction con-
ditions without cellular toxicity. So, at a two-fold lower
MOI, a single exposure of GEN2.2 to GaLV-LV led to only
13.3% +/- 5.5% of E-GFP positive cells (figure 1A). Similar
results were obtained on human CD34-pDC transduced
at day 6 (figure 2A) and monitored 6 days posttransduc-
tion. Long-term expression of the transgene for GEN2.2
was maintained in all cases until at least day 60, as
checked by flow cytometry (data not shown).
In a second step, we then selected the VSVG-LV pseudo-
type at MOI of 18 to transduce the pDC cell line, and eval-
uated the expression of GFP under the control of different
promoters such as the ubiquitous PGK promoter, the
hematopoietic cell-specific EF1 promoter, the muscle-spe-
cific desmin and the synthetic C512 promoters. The per-
centage of E-GFP+ cells obtained was very high with both
EF1 (79% +/- 15.3%) and C5–12 (94% +/- 2.8%) promot-
ers which are 2.6 to 3 more efficient than the PGK pro-
moter for transducing GEN2.2 (figure 1B). Surprisingly, a
second muscle-specific promoter, desmin, was also highly
efficient in pDC, since 47.7% +/- 11.1% of cells were E-
GFP+ (figure 1B). Similar results were obtained on human
CD34-pDC transduced at day 6 (figure 2B) and moni-
tored 6 days posttransduction. Altogether, these results
show that VSVG-pseudotyped LV encoding the E-GFP as
transgene under the control of the EF1 or C5–12 promot-
ers are very efficient for transduction of pDC.
Immunophenotype of transduced pDC Figure 3
Immunophenotype of transduced pDC. Comparative phenotypes of transduced and untransduced GEN2.2 in absence of 
maturation agent, at day 5. Overlay histograms show the expression of CD123 or HLA-DR for untransduced (thin line), total 
transduced (thick line) and E-GFP+ gated (green line) GEN2.2, versus isotype-matched controls (dotted line). (A) GEN2.2 
transduced by LV with a PGK promoter pseudotyped with either VSVG, RD114 or GaLV envelopes. (B) GEN2.2 were trans-
duced with VSVG pseudotyped-LV with a PGK, EF1, desmin or C5–12 promoter (C) GEN2.2 were transduced by rAAV of 
serotype 1, 2 or 5 with a CMV promoter. The results are representative of at least 4 experiments.
Transduction of GEN2.2 does not induce maturation Figure 4
Transduction of GEN2.2 does not induce maturation. 
Comparative phenotype of transduced and non transduced 
GEN2.2. Overlay histograms show the expression of rele-
vant antigens for untransduced (thin line) and transduced 
(thick line) with LV-VSVG/PGK or rAAV2/2, versus isotype-
matched controls (dotted line). The results are representa-
tive of at least 3 experiments.Journal of Translational Medicine 2009, 7:10 http://www.translational-medicine.com/content/7/1/10
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In a similar protocol, we used AAV vectors of different
serotypes (rAAV2/1, rAAV2/2 and rAAV2/5) to transduce
the pDC cell line and CD34-pDC and compared their effi-
cacy. We previously showed that single-stranded rAAV2/1
and rAAV2/2 were very poorly efficient in transducing
human pDC generated in vitro from CD34+ progenitor
cells [38]. We evaluated here, whether cells fully differen-
tiated into pDC could be transduced by rAAV of serotypes
1 and 2, but also of serotype 5. Preliminary experiments
performed with different amounts of viral particles (5 ×
103 to 5 × 104 vg/cell), at a fixed cell density, showed that
maximum transduction levels were reached with 2.5 × 104
vg/cell for rAAV2/1 and rAAV2/2 and with 9 × 103 vg/cell
for rAAV2/5, with no cellular toxicity (data not shown).
GEN2.2 and CD34-pDC were monitored for CD123,
HLA-DR and E-GFP expression, but only at day 5 to 6
posttransduction, since pDC are dividing cells and AAV
vectors are mainly episomal. A single exposure of pDC to
rAAV2/1, rAAV2/2 or rAAV2/5 led to very low levels of
transduced cells ranging from around 3% to less than 1%
of E-GFP+ cells (figure 1C and 2C). These results indicate
that pDC are not susceptible to transduction by single-
strand AAV vectors of serotype 1, 2 or 5.
Immunophenotypical analysis of transduced pDC
The GEN2.2 cell line was previously characterized by its
phenotype as a pDC cell line. These cells have been shown
to express the human leukocyte antigen-DR (HLA-DR),
the IL3-receptor (CD123) and the CD4 [18]. Moreover, as
a hallmark of pDC, these cells are BDCA2 and BDCA4
(type II C lectin)-positive and CD11c- and CD1a-negative.
Trypan blue exclusion and cell counting of LV and rAAV
transduced GEN2.2 at the end of the culture period indi-
cated that transduction had no deleterious effect on cell
viability compared to control cells (data not shown). We
explored in detail the immunophenotype of these trans-
duced and control GEN2.2 by flow cytometry. We showed
that whatever lentiviral or rAAV vectors used to trans-
CpG induced maturation of transduced pDC Figure 5
CpG induced maturation of transduced pDC. Comparative phenotype of transduced GEN2.2, 6 days posttransduction, 
in the absence and presence of CpG for 24 hours. Overlay histograms show the expression of relevant antigens for transduced 
GEN2.2 cultured without CpG (thin line), with CpG (thick line) and with CpG and gated on E-GFP+ (green line) versus isotype-
matched controls (dotted line). (A, B, C) Transduced GEN2.2 vectors are the same ones as those described in figure 2. Values 
indicated are MFI of the transduced populations cultured without CpG versus transduced populations cultured with CpG. The 
results are representative of at least 4 experiments.Journal of Translational Medicine 2009, 7:10 http://www.translational-medicine.com/content/7/1/10
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duced the GEN2.2 cells, no significant modification of the
CD123 and HLA-DR expression (figure 3) of the CD4,
BDCA2 and BDCA4 (data not shown) or of the costimu-
latory molecules and maturation marker CD80, CD86,
CD40 and CD83 as illustrated figure 4, with two vectors,
was observed, compared to control cells. Comparative
phenotypic analysis of unactivated and CpG-activated
transduced GEN2.2 revealed a normal upregulation of the
co-stimulatory molecule CD86, demonstrating that the
maturation capacity of transduced subpopulations was
unaltered (Figure 5). Similarly, the phenotype of human
transduced CD34-pDC was not modified compare to
non-transduced cells (data not shown). Our results indi-
cate that the LV transduction does not alter the phenotype
of pDC or their capacity to mature.
Functional properties of transduced pDC
We evaluated the ability of different transduced GEN2.2
to stimulate allogeneic T cells in an allogeneic mixed lym-
phocyte reaction (MLR). GEN2.2 transduced with the dif-
ferent E-GFP encoding vectors were matured with CpG for
24 hours, then sorted by flow cytometry on the basis of E-
GFP expression. Non-transduced, E-GFP negative and
positive sorted GEN2.2 were used for stimulation of allo-
geneic T-cells labelled with CFSE. Both negative and posi-
tive E-GFP GEN2.2 populations displayed similar
T-cell stimulatory capacity of non-transduced and transduced GEN2.2 in mixed lymphocyte alloreactions Figure 6
T-cell stimulatory capacity of non-transduced and transduced GEN2.2 in mixed lymphocyte alloreactions. Day 
5 transduced GEN2.2 were matured in CpG for 24 hours, before cell sorting on an E-GFP expression basis. (A-E) Total non-
transduced (NT), E-GFP- and E-GFP+cell sorted GEN2.2 transduced by the same LV as those described in figure 3 were incu-
bated with allogeneic T cells stained with CFSE. (F) Total non-transduced (NT) and rAAV2/1, rAAV2/2 or rAAV2/5 transduced 
unsorted GEN2.2 were incubated with allogeneic T-cells stained with CFSE. After 4 days of co-culture, percentages of CD3+ 
dividing T cells measured by flow cytometry were linearly correlated with the loss of CFSE fluorescence. Dot plots inserted in 
graphs show one representative CFSE profile at the ratio 3/1 for GFP+ cells. The data are shown as the means of 3 independent 
experiments.Journal of Translational Medicine 2009, 7:10 http://www.translational-medicine.com/content/7/1/10
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allostimulatory capacity compared to non-transduced
GEN2.2, whatever vector used (figure 6 and data not
shown). In response to these viruses, pDC are known to
secrete high levels of type I IFN [14,15]. Of note, IFN-α
was not detected in cell supernatant of any transduced
GEN2.2 cultures when checked between 24 hours and 10
days following contact with the different viral particles.
Nevertheless, GEN2.2 and CD34-pDC were always able to
secrete IFN-α upon stimulation by the CpG motif via the
toll-like receptor signalling pathway, as illustrated figure 7
for pDC transduced with a LV pseudotyped with VSVG
coding for E-GFP under the control of the PGK promoter.
Moreover, we evaluated the capacity of the HLA-A0201
expressing pDC to activate a CD8+ T cell clone after trans-
duction with a LV coding for the MART-1 peptide under
the control of the PGK promoter. The transduced GEN2.2
obtained were efficient in activating a specific CD8+ T-cell
clone (Figure 8A). Results were confirmed on CD34-pDC
transduced with the same LV expressing a MART-1 peptide
(Figure 8B). Interestingly these transduced CD34-pDC
were as efficient as Mo-DC for activation of a specific
CD8+ T cell clone (Figure 8B).
Altogether, these results indicate that the functional prop-
erties of pDC were not altered by LV or rAAV transduction.
Furthermore, LV-transduced pDC were able to activate a
CD8+ T-cell clone.
Discussion
The attractiveness of dendritic cells as a target for genetic
manipulation is a consequence of their ability to initiate
and orchestrate primary immune responses, including
tolerogenic responses [1,45,46]. At least two circulating
subsets of DC have been described: myeloid DC and pDC
with evidence of functional differences in their ability to
regulate the T-cell responses, to produce antiviral type I
IFN and to cross-present exogenous antigens to CD8+ T
cells [47]. We previously showed that VSVG-pseudotyped
HIV-1 vectors are good candidates for efficient transduc-
tion of monocyte- and CD34+-derived LC, without induc-
ing phenotypic and functional maturation [26]. More
recently, we also showed that self-complementary duplex
strands but not single strands rAAV2/1 and 2 were also
very efficient in transducing major DC subsets generated
in vitro, including CD34+-derived pDC [38].
In this study, we extended LV transduction to pDC, using
different pseudotyped HIV-1 vectors encoding E-GFP
under the control of different promoters and showed that
VSVG-pseudotyped LV encoding E-GFP under the control
of EF1 or C512 promoters are the most efficient combina-
tions, leading to transduction of 60% to 90% of the pDC
cell line, GEN2.2 [18] and CD34-pDC. Of note, we
showed that transduction did not alter alloreactive pres-
entation properties of pDC. Furthermore, pDC trans-
duced with LV expressing a MART-1 peptide was as
efficient as Mo-DC for activation of a specific CD8+ T cell
clone. Altogether, these results show that antigen-loading
of pDC through ex-vivo LV transduction may represent a
relevant immunotherapy approach for particular clinical
applications. Indeed, compared with antigen loading pro-
tocols using whole tumor cell lysates or recombinant
tumor-associated antigen peptides, LV transduction offers
the advantage of direct antigen processing from cytosolic
proteins and of long lasting antigen expression.
Previous publications [30-32] reported efficient transduc-
tion levels of hematopoietic cells with LV pseudotyped
with GaLV or RD114 envelopes. Here, the highest pDC
transduction levels were obtained with the VSVG enve-
lope, which was also previously shown to efficiently trans-
duce human hematopoietic progenitor and leukaemia
cells [26,48,49] as well as fully differentiated human
monocyte-derived DC [50,51], with a long lasting expres-
sion. The EF1α promoter was shown to have a stronger
activity than the PGK promoter in a human CD34+ cell
line [33] and in cultured cord blood cells [33,34] and
allowed to obtain transgene-expressing myeloid DC [23].
Here, we showed that after a single exposure to VSVG-
pseudotyped LV, the percentage of E-GFP expressing pDC
was 2.6 fold higher when the expression was driven by the
EF1 compared to the PGK promoter. The average copy
number of the vector in transduced pDC under both con-
ditions was similar (3–4 copies per cell), as determined by
real-time quantitative PCR (data not shown). This indi-
cates that the integration levels are similar with both con-
structions but that, as previously described, the promoter
activity is different. We also evaluated two other promot-
ers described to be muscle restricted [39-41], the desmin
IFN-α production by pDC Figure 7
IFN-α production by pDC. GEN2.2 and day 6 CD34-pDC 
were non transduced (NT) or transduced by LV-VSVG at an 
MOI of 18 (LV-VSVG), then 6 days later, the IFNα produc-
tion was measured in cell culture supernatants before or 
after maturation in CpG, for 24 hours. The data are shown 
as the means of 3 independent experiments.Journal of Translational Medicine 2009, 7:10 http://www.translational-medicine.com/content/7/1/10
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and synthetic C512 promoters which have been shown in
gene therapy studies to specifically target muscles and to
drive gene expression in a context of ss rAAV vectors [41].
As in our previous report [38], we showed here that even
with an ubiquitous promoter like CMV, only a very low
transduction efficiency could be reached with ss rAAV in
the different DC subsets. So, in order to investigate the
potential leak of these promoters in human DC subsets,
we constructed and produced LV vectors carrying the two
different cassettes. Surprisingly, we showed that the per-
centages of E-GFP expressing pDC with desmin and C512
promoters were very high and equivalent to those
obtained with PGK and EF1 promoters, respectively. The
average copy number in pDC for desmin and C512 pro-
moters were 4 and 1 copies per cell, respectively, showing
that the C512 promoters was at least as efficient as an
ubiquitous promoter (data not shown). In contrast to the
desmin promoter, the C512 promoter was also active in
monocyte-derived DC and LC (around 10% of E-GFP+
cells) and in a human colorectal carcinoma (HCT116)
(data not shown). Nevertheless, transgene expression
with these cassettes in ss AAV vectors was not detectable
(data not shown). Taken together, these data suggest that
the use of desmin or C5–12 promoters in ss rAAV, for clin-
ical gene therapy protocols, will not induce transgene
expression in DC subsets. Nevertheless, the use of these
promoters in sc rAAV, which are highly efficient for trans-
ducing major DC subsets [38] might elicit high immune
responses against the transgene.
Conclusion
DC transduction with LV preparations can serve as vaccine
vehicles in human through efficient transduction levels
and are also useful in vitro to evaluate the immunogenicity
of the vector preparations and the specificity and safety of
promoters used in gene therapy protocols.
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